APA (7th ed.) Citation

R, G., S, Y., S, G., P, P., N, R., K, P., . . . G, B. (2024). Rituximab-to-vaccine interval on SARS-CoV-2 immunogenicity in children: The potential role of prior natural infection. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 35(5), e14161. https://doi.org/10.1111/pai.14161

Chicago Style (17th ed.) Citation

R, Gualtieri, Yerly S, Garcia-Tarodo S, Parvex P, Rock N, Posfay-Barbe K, Didierlaurent AM, Eberhardt C, and Blanchard-Rohner G. "Rituximab-to-vaccine Interval on SARS-CoV-2 Immunogenicity in Children: The Potential Role of Prior Natural Infection." Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology 35, no. 5 (2024): e14161. https://doi.org/10.1111/pai.14161.

MLA (9th ed.) Citation

R, Gualtieri, et al. "Rituximab-to-vaccine Interval on SARS-CoV-2 Immunogenicity in Children: The Potential Role of Prior Natural Infection." Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology, vol. 35, no. 5, 2024, p. e14161, https://doi.org/10.1111/pai.14161.